Maravai LifeSciences Holdings, Inc. (MRVI)
| Market Cap | 1.80B +163.4% |
| Revenue (ttm) | 208.78M -5.0% |
| Net Income | -77.39M |
| EPS | -0.53 |
| Shares Out | 259.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 701,583 |
| Open | 6.90 |
| Previous Close | 6.88 |
| Day's Range | 6.79 - 7.09 |
| 52-Week Range | 2.55 - 9.42 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 7.42 (+7.3%) |
| Earnings Date | Nov 5, 2026 |
About MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents ... [Read more]
Financial Performance
In 2025, MRVI's revenue was $185.74 million, a decrease of -28.34% compared to the previous year's $259.19 million. Losses were -$130.77 million, -9.72% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for MRVI stock is "Buy." The 12-month stock price target is $7.42, which is an increase of 7.30% from the latest price.
News
Maravai Lifesciences initiated with a Neutral at UBS
UBS analyst Doug Schenkel initiated coverage of Maravai Lifesciences (MRVI) with a Neutral rating and $8 price target The firm initiated and resumed 25 life science and diagnostics tools companies.
Stifel sees Moderna data as positive for Repligen, Maravai
Stifel views Moderna’s (MRNA) Phase 3 INTerpath-001 data as good for Repligen (RGEN) and “conceptually good” for Maravai Lifesciences (MRVI). Repligen called out specific involvement in Moderna and Me...
Maravai LifeSciences Holdings Earnings Call Transcript: Q2 2026
Q2 2026 saw 9% revenue growth, margin expansion, and strong execution across both segments. TriLink's GMP consumables and discovery mRNA drove results, while Cygnus maintained steady growth. Guidance remains prudent due to variability in large orders, but profitability and liquidity have improved.
Maravai LifeSciences Holdings Earnings release: Q2 2026
Maravai LifeSciences Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Maravai LifeSciences Holdings Slides: Q2 2026
Maravai LifeSciences Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Maravai LifeSciences Holdings Quarterly report: Q2 2026
Maravai LifeSciences Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Maravai LifeSciences Reports Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported ...
Maravai LifeSciences Holdings Slides: Investor presentation
Maravai LifeSciences Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its se...
Maravai’s TrinLink BioTechnologies granted new patent in China
TriLink BioTechnologies, a Maravai LifeSciences (MRVI) company, has been granted a new patent from the China National Intellectual Property Administration, Patent number ZL 2025 1 1246578.X, covering ...
TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted a new pat...
Maravai Lifesciences announces opening of GMP enzyme manufacturing facility
TriLink, part of Maravai LifeSciences (MRVI), announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scal...
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
JUPITER, Fla.--(BUSINESS WIRE)--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA th...
Maravai LifeSciences Holdings Transcript: Jefferies Global Healthcare Conference 2026
Significant cost reductions and operational streamlining have driven improved margins and cash flow. Commercial execution, product innovation (notably ModTail), and e-commerce expansion are fueling growth, with further upside expected from new product launches and geographic expansion, especially in China.
Maravai Lifesciences announces refinancing of credit agreement
Maravai LifeSciences (MRVI) Holdings announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150M term loan facility and a $30M revolving…
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that cert...
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company w...
Maravai Lifesciences price target raised to $6 from $4.50 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Maravai Lifesciences (MRVI) to $6 from $4.50 and keeps a Buy rating on the shares.
Maravai LifeSciences Holdings Slides: Investor presentation
Maravai LifeSciences Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
Maravai LifeSciences Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 41% revenue growth year-over-year, strong TriLink and Cygnus performance, and positive free cash flow. Full-year guidance was raised for both revenue and EBITDA, driven by high-margin GMP consumables and operational improvements.
Maravai LifeSciences Holdings Earnings release: Q1 2026
Maravai LifeSciences Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Maravai LifeSciences Holdings Slides: Q1 2026
Maravai LifeSciences Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Maravai LifeSciences Holdings Quarterly report: Q1 2026
Maravai LifeSciences Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.
Maravai LifeSciences Reports First Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported ...
Maravai LifeSciences Holdings Proxy statement: Proxy filing
Maravai LifeSciences Holdings filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.